30 Jun 2010 07:00
30 June 2010
Toumaz Limited
Half year trading update
Toumaz Limited (AIM: TMZ, 'Toumaz', or 'the Group'), a pioneer in low cost, ultra low power wireless communications technology, has published a half year trading update for the six months to the end of June 2010. The Group has traded in line with the Board's expectations and as at 28 June 2010 had a cash balance of £5.6m. Operational progress has been made in both healthcare applications and consumer focussed products.
Healthcare
The Group has continued to develop and license its "body area networks" for end-to-end healthcare systems. The Sensium is an ultra low power technology platform that provides unobtrusive, continuous, wireless monitoring of vital signs that enables the analysis and interpretation of physiological data.
The first trials at St. Mary's Hospital were successfully completed in February and further trials of the complete end-to-end system are expected to start in Q4 2010. This will clear the way for FDA and CE regulatory filing during 2011, with the first royalty revenues expected in the latter part of that year.
Toumaz is also progressing as planned with the design of the next generation of integrated circuit for the Sensium platform. This update adds to the capabilities of the integrated circuits behind the Sensium platform and will help reduce the overall cost of the solutions.
Consumer
Toumaz supplies DAB/FM devices to Pure for their DAB/FM products. In April this year the Group launched the Milton DAB/FM module to address a wider digital radio customer base. Good progress is being made in getting Milton designed into a number of digital radio customers, some of which the Group expects to start shipping for the 2010 Christmas market.
The engineering and characterisation of the next generation of wireless connectivity and internet audio products, TELRAN and XENIF are on course for launch late in 2010. These products will extend further Toumaz's reach into the internet connected consumer market with the integration of DAB/wifi/processor into one chip, so providing a smaller, lower cost solution.
Toumaz expects to publish its interims results in mid September.
Enquiries:
| Toumaz Holdings Limited | 020 7355 0036 |
| Chris Toumazou, Chief Executive Officer |
|
| Patrick Stephansen, Chief Financial Officer |
|
|
|
|
| FinnCap | 020 7600 1658 |
| Marc Young (Corporate Finance) |
|
| Brian Patient (Corporate Broking) |
|
|
|
|
| College Hill | 020 7457 2020 |
| Adrian Duffield/Rozi Morris |
|
About Toumaz (www.toumaz.com)
Toumaz is pioneering low cost, ultra-low power wireless technologies for a wide range of markets including medical monitoring and internet-connected consumer devices.
Targeting the Healthcare market, Toumaz's licensable smart sensor interface and transceiver platform, Sensium, is a leader in real-time wireless monitoring of the body's vital signs. Sensium has the potential to transform medical monitoring and reduce the cost of healthcare by wirelessly connecting individuals to healthcare providers - simply, affordably and unobtrusively. For healthcare professionals, this creates new opportunities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible personalised healthcare.
Toumaz also uses its ultra low power expertise to design devices for wireless connectivity and internet-connected consumer products. Toumaz currently supplies FM/DAB radio chips and complete modules to leaders in the digital radio market, such as PURE.
Toumaz is an AIM listed company (AIM: TMZ) with development centres in Oxford, UK and Taipei City, Taiwan.